Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Intas
Pharmaceutical Preparation ManufacturingIndiaXETRA: CIT.DE
Last verified 2 years agointaspharma.com
Intas Pharmaceuticals Ltd., widely recognised as Intas, is a prominent global pharmaceutical company headquartered in Ahmedabad, India. Founded in 1977, it has evolved into a significant player in the pharmaceutical preparation manufacturing industry, driven by a commitment to healthcare innovation.
As one of India's leading pharmaceutical organisations, Intas boasts a formidable global footprint, operating in over 85 countries. The company is renowned for developing and delivering affordable, high-quality therapeutic solutions across diverse areas including oncology, CNS, cardiovascular, and immunology.
Intas is dedicated to enhancing patient lives through its extensive portfolio of innovative and accessible medicines. This unwavering commitment to ethical practices and scientific excellence has solidified its position as a trusted name in healthcare worldwide.
20
DitchCarbon score
-22 vs industry average
Intas’s score of 20 is lower than 21% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Intas?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Intas yet.
Intas's reported carbon emissions
Intas, headquartered in India, currently does not report any carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the company has not established specific reduction targets or commitments under initiatives such as the Science Based Targets initiative (SBTi) or other climate pledges.
In the absence of reported emissions and reduction initiatives, it is unclear how Intas is addressing its carbon footprint or contributing to climate action within the pharmaceutical industry. As the sector increasingly focuses on sustainability, it is essential for companies like Intas to develop and communicate their climate commitments to align with global efforts in reducing greenhouse gas emissions.
Assessing Intas as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Intas and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Intas’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Intas yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Intas2 years ago
20
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more